Product Name:Bremelanotide
Synonyms:PT-141, PT141
CAS No.:189691-06-3 ,1607799-13-2
Catalog No.:GT-A005
Key Specification:
Appearance: White powder
Purity (HPLC) ≥98.0%
Single impurity≤1.0%
Acetate Content(HPLC)≤10.0%
Water Content (Karl Fischer) ≤8.0%
Peptide content≥80.0%
Package:
Vacuum-packed with aluminum foil bag or transparent bag. 500mg,1g, 10g,50g 100g per package with icebag. Or according to your request.
Description:
Bremelanotide was developed by Palatin Technologies, it was first described in the literature in 2003 when it was known by the investigational code PT-141.Bremelanotide was granted FDA approval on 21 June 2019.
Storage:Cool dry place( Store at -20°C, away from the light)
Background:
Bremelanotide was developed by Palatin Technologies and was approved for use in the United States by FDA in June 21, 2019.
Remarks
Products currently covered by valid Patents are offered for R&D use.
Any patent infringement and resulting liability is solely at buyer risk.
